Additional file 1 of Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

Autor: Chen, Timothy L., Harrington, Bonnie, Truxall, Jean, Wasmuth, Ronni, Prouty, Alexander, Sloan, Shelby, Lehman, Amy M., Sampath, Deepa, Orlemans, Eric, Baiocchi, Robert A., Alinari, Lapo, Byrd, John C., Woyach, Jennifer A., Hertlein, Erin
Rok vydání: 2021
DOI: 10.6084/m9.figshare.14111354.v1
Popis: Additional file 1. Eμ-BRD2 in vivo model. A Kaplan–Meier estimates of overall survival in mice engrafted with ibrutinib resistant BRD2 splenocytes and treated with vehicle, ibrutinib (30 mg/kg daily in drinking water), SNX-5422 (50 mg/kg 3 days/week) or the combination. B Mice spleens were weighed at early removal criteria and compared between treatment groups. C Histopathology performed on spleen, lymph node, liver, lung and bone marrow reveals reduced leukemic infiltration in the liver, lungs, and marrow of SNX-5422 and SNX-5422 + ibrutinib treated groups. (C, lymph node cortex; M, lymph node medulla; W, spleen white pulp; R, spleen red pulp).
Databáze: OpenAIRE